search
Documents
Aggregate Analysis of Semaglutide Using a Biozen dSEC-1 SEC Column
This technical note highlights the use of Biozen dSEC-1 SEC columns for monitoring aggregation in Semaglutide, a GLP-1 receptor agonist used in diabetes and obesity management. The hydrophilic stationary phase minimizes non-specific interactions, eliminating the need for high organic or acidic mobile phases. Using a 150 mm (1.6 um) column, monomer and two aggregate species were baseline-resolved (Rs > 3.1) in a 12-minute run, with excellent reproducibility (retention time RSD less than 0.28%, peak area RSD less than 4.02%) and high sensitivity (S/N > 26 for aggregates). Biozen dSEC-1 provides a robust, reproducible solution for Semaglutide aggregation analysis under mild conditions.
Aggregate Analysis of Semaglutide Using a Biozen dSEC-1 SEC Column
This technical note highlights the use of Biozen dSEC-1 SEC columns for monitoring aggregation in Semaglutide, a GLP-1 receptor agonist used in diabetes and obesity management. The hydrophilic stationary phase minimizes non-specific interactions, eliminating the need for high organic or acidic mobile phases. Using a 150 mm (1.6 um) column, monomer and two aggregate species were baseline-resolved (Rs > 3.1) in a 12-minute run, with excellent reproducibility (retention time RSD less than 0.28%, peak area RSD less than 4.02%) and high sensitivity (S/N > 26 for aggregates). Biozen dSEC-1 provides a robust, reproducible solution for Semaglutide aggregation analysis under mild conditions.
Document Type:
Technical Notes
Target Industries:
Brands:
Separation Modes:
Size Exclusion
Phases:
Aggregate Analysis of Semaglutide Using a Biozen dSEC-1 SEC Column
This technical note highlights the use of Biozen dSEC-1 SEC columns for monitoring aggregation in Semaglutide, a GLP-1 receptor agonist used in diabetes and obesity management. The hydrophilic stationary phase minimizes non-specific interactions, eliminating the need for high organic or acidic mobile phases. Using a 150 mm (1.6 um) column, monomer and two aggregate species were baseline-resolved (Rs > 3.1) in a 12-minute run, with excellent reproducibility (retention time RSD less than 0.28%, peak area RSD less than 4.02%) and high sensitivity (S/N > 26 for aggregates). Biozen dSEC-1 provides a robust, reproducible solution for Semaglutide aggregation analysis under mild conditions.
| Target Industries: | Biopharmaceutical Analysis |
| Techniques: | HPLC, HPLC-SEC |
| Brands: | Biozen LC |
| Separation Modes: | Size Exclusion |
| Phases: | Biozen dSEC-1 |
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide.
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide.